Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.54 |
| ▸ | AKT2 | P31751 | 2/20 | 0.54 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.54 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GLS | O94925 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3110870 | 0.87 | MCHR1 (0.45) | AKT1AKT2AKT3CHRM4LMNA | |
| SCHEMBL12437795 | 0.86 | UTS2R (0.47) | AKT1AKT2AKT3UTS2RCCR3 | |
| SCHEMBL12513958 | 0.84 | SLC6A2 (0.54) | UTS2RCCR3 | |
| SCHEMBL3109712 | 0.83 | MCHR1 (0.45) | AKT1AKT2AKT3MEN1KMT2A | |
| SCHEMBL12437913 | 0.81 | UTS2R (0.48) | UTS2RCHRM4LMNAMEN1KMT2A | |
| SCHEMBL12437829 | 0.81 | CACNA1G (0.54) | UTS2R | |
| SCHEMBL12437718 | 0.80 | MEN1 (0.46) | UTS2RCCR3MEN1KMT2A | |
| SCHEMBL17946117 | 0.80 | UTS2R (0.55) | UTS2RCCR3MEN1KMT2A | |
| SCHEMBL12437721 | 0.79 | MEN1 (0.45) | UTS2RCCR3MEN1KMT2A | |
| SCHEMBL12437722 | 0.79 | UTS2R (0.45) | UTS2RCCR3LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | AVALON PHARMACEUTICALS | 2011-07-21 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | AVALON PHARMACEUTICALS | 2009-02-05 | — | — | US | disclosed |
| WO-2007098086-A2 | HYDROXYPIPERIDINE DERIVATIVES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178066-A1 | Hydroxypiperidine derivatives and uses thereof | HPGDS, HPGD, DPYD | AKT1 3346/4885AKT2 2541/4885AKT3 2316/4885 |
| US-20090036429-A1 | Hydroxypiperidine Derivatives and Uses Thereof | HPGDS, HPGD, DPYD | AKT1 3346/4885AKT2 2541/4885AKT3 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.